John joined Karyopharm in March 2020 and leads the Company’s commercial strategy and operations, including the sales, marketing, and market access functions.
Prior to joining Karyopharm, John served as Chief Commercial Officer at G1 Therapeutics where he developed the commercial vision for the company’s oncology assets and led its integrated commercial function. Prior to G1, John served as Vice President, Oncology Marketing at Astellas, where he was responsible for establishing and leading the oncology marketing function, including the successful launch of Xtandi® (enzalutamide). He oversaw the commercial strategy and execution for two approved products and three compounds in development, as well as market access and reimbursement strategy and external commercial collaborations. Previously, John led oncology business development and alliance management at Abbott. He began his career serving in marketing leadership positions at Novartis and Eli Lilly.
John holds an MBA in Marketing and Finance from Indiana University and a B.S. in Marketing, also from Indiana University.